Navamedic ASA: National approvals of Flexilev® in OraFID® granted across all Nordic countries.

13 Aug 2025 09:51 CEST

Oslo, Norway - 2025.08.13 - Navamedic is pleased to announce that it has
received final approval for the packaging material in national languages for
Norway, Sweden and Denmark, following the earlier announcement on June 27th.
Orion Corporation ("Orion"), the product licensor for Finland and the rest of
the EU, has also obtained final confirmation for the Finnish market.

"We are excited to have received the last approvals, paving the way for our go
-to-market launch in the Nordic region," said Kathrine Gamborg Andreassen, Chief
Executive Officer of Navamedic.
Flexilev® in OraFID® ensures precise and personalized treatment tailored to
individual Parkinson's Patient needs. Medications with a narrow therapeutic
window can benefit from hyper-fractionation, which involves administering
smaller, more frequent doses.
OraFID® is a unique, patented, fully mechanical medical device that dispenses
precise quantities of minitablets with just a few of twists of the hands.
The launch in the Nordic markets is still anticipated in October 2025.
For further information, please contact:

Kathrine Gamborg Andreassen, CEO, NavamedicLars Hjarrand, CFO, Navamedic
Mobile: +47 951 78680Mobile: +47 917 62842
E-mail: kathrine@navamedic.comE-mail: lars.hjarrand@navamedic.com
About Navamedic

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's
quality of life by being a reliable supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies. Our growing
product portfolio has been carefully selected to meet current public health
concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to
empower people to live healthier and more fulfilling lives.

What sets us apart is our deep-rooted commitment to understanding the needs and
requirements of the countries where we are present. Our local insight and
competence enable us to understand the specific needs of each country where we
operate and ultimately to gain market access. This makes us a preferred partner
for international companies expanding their footprint across the Nordics and
Benelux regions, through either in-licensing or out-licensing. Navamedic has
been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is
headquartered in Oslo, Norway.

For more information, please visit Navamedic.com
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site